Home healthcare provider Addus HomeCare (NASDAQ:ADUS) will be reporting earnings tomorrow after the bell. Here’s what investors should know. Addus HomeCare beat analysts’ revenue expectations by 2.7% last quarter, reporting revenues of $297.1 million, up 7.5% year on year. It was a very strong quarter for the company, with an impressive beat of analysts’ sales volume estimates and a decent beat of analysts’ EPS estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it’s free. This quarter, analysts are expecting Addus HomeCare’s revenue to grow 21.1% year on year to $339.9 million, improving from the 11.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.33 per share.Addus HomeCare Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street’s revenue estimates three times over the last two years. Looking at Addus HomeCare’s peers in the senior health, home health & hospice segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Option Care Health delivered year-on-year revenue growth of 16.3%, beating analysts’ expectations by 6.1%, and Chemed reported revenues up 9.8%, topping estimates by 0.8%. Option Care Health traded down 2% following the results while Chemed was also down 6.9%. Read our full analysis of Option Care Health’s results here and Chemed’s results here. There has been positive sentiment among investors in the senior health, home health & hospice segment, with share prices up 4.9% on average over the last month. Addus HomeCare is up 8.2% during the same time and is heading into earnings with an average analyst price target of $135.70 (compared to the current share price of $105). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. View Comments
Addus HomeCare (ADUS) Reports Earnings Tomorrow: What To Expect
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...